Department of Dermatology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8429-8438. doi: 10.26355/eurrev_202008_22640.
Melanoma is one of the most malignant types of skin tumors and accounts for the majority of skin cancer-related deaths. LINC00662 is a tumor promoter in multiple types of cancer, but the role of LINC00662 in melanoma has not been fully elucidated.
The expression levels of LINC00662, miR-890, and ELK3 were detected by Real Time-quantitative Polymerase Chain Reaction (RT-qPCR). MTT assay was performed to measure the cell proliferation ability in A375 and SK-MEL-1 cells. Cell migration and invasion abilities were measured by wound healing assay and transwell assay, respectively. Besides, Luciferase reporter assay was employed to examine the interaction between miR-890 and LINC00662 or ELK3.
In the present study, it was demonstrated that melanoma patients with high expression levels of LINC00662 had a shorter survival time than those with low expression levels of LINC00662. LINC00662 exhibited higher expression levels in melanoma tissues and cell lines. Additionally, suppression of LINC00662 impaired cell proliferation, migration, and invasion. Furthermore, animal experiments demonstrated that LINC00662 facilitated tumor growth in vivo. LINC00662 was confirmed to bind with miR-890, and ELK3 was identified as a downstream target gene of miR-890. Furthermore, miR-890 was found to negatively regulate ELK3 expression. Through rescue assays, overexpression of ELK3 reversed the inhibitive effects of LINC00662 knockdown or miR-890 mimics on the cell proliferative, migratory, and invasive abilities.
Our results demonstrated that LINC00662 facilitated the occurrence and development of melanoma by sponging miR-890 to upregulate ELK3. This discovery implied that LINC00662 may be a promising prognostic and therapeutic biomarker for patients with melanoma.
黑色素瘤是最恶性的皮肤肿瘤之一,占皮肤癌相关死亡人数的大部分。LINC00662 是多种类型癌症的肿瘤促进剂,但 LINC00662 在黑色素瘤中的作用尚未完全阐明。
通过实时定量聚合酶链反应(RT-qPCR)检测 LINC00662、miR-890 和 ELK3 的表达水平。通过 MTT 测定法测量 A375 和 SK-MEL-1 细胞中的细胞增殖能力。通过划痕愈合测定法和 Transwell 测定法分别测量细胞迁移和侵袭能力。此外,还采用荧光素酶报告基因测定法检测 miR-890 与 LINC00662 或 ELK3 之间的相互作用。
在本研究中,证实黑色素瘤患者中 LINC00662 高表达者的生存时间短于 LINC00662 低表达者。LINC00662 在黑色素瘤组织和细胞系中表达水平较高。此外,抑制 LINC00662 可损害细胞增殖、迁移和侵袭。此外,动物实验表明 LINC00662 促进了体内肿瘤的生长。证实 LINC00662 与 miR-890 结合,ELK3 被鉴定为 miR-890 的下游靶基因。此外,发现 miR-890 负调控 ELK3 的表达。通过挽救实验,过表达 ELK3 逆转了 LINC00662 敲低或 miR-890 模拟物对细胞增殖、迁移和侵袭能力的抑制作用。
我们的研究结果表明,LINC00662 通过海绵 miR-890 来上调 ELK3,促进黑色素瘤的发生和发展。这一发现表明 LINC00662 可能成为黑色素瘤患者有前途的预后和治疗生物标志物。